May 2023 Vol 16, No 3

The May issue of The Oncology Pharmacist contains valuable news and updates for today’s oncology pharmacist, including the latest data from clinical trials evaluating the safety and efficacy of novel therapies being used to treat a variety of cancers; highlights from the recent National Comprehensive Cancer Network Annual Conference; key takeaways from a survey documenting the ways in which inflation is affecting how consumers make decisions regarding their healthcare; and details on an innovative program being offered by the American Society of Health-System Pharmacists with the goal of helping pharmacists combat burnout in the workplace. Read More ›

Vaccination against human papillomavirus can prevent several types of cancer, including cervical, oral/oropharyngeal, penile, and anal cancers. Read More ›

The consumption of ultra-processed foods is associated with an increased risk for cancer and cancer-related death, according to findings from a recent study. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between February 9, 2023, and April 3, 2023. Read More ›

The FDA has issued a final rule intended to ensure patients are better informed about their breast tissue density when undergoing mammography. Read More ›

In a session during the 2023 National Comprehensive Cancer Network Annual Conference, Deborah M. Stephens, DO, provided important updates to treatment recommendations for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, and identified key factors for selecting frontline and subsequent therapies, including immunoglobulin heavy chain variable gene status, 17p deletion/TP53 mutation status, age, patient comorbidities, and resistance mutations. Read More ›

Surgery is typically the gold standard for patients with biopsy-proven, clear cell, renal cell carcinoma with no evidence of metastatic disease, said Eric Jonasch, MD, in a session during the 2023 National Comprehensive Cancer Network Annual Conference. In this setting, there is probably not a role for systemic neoadjuvant treatment, as response rates of 15% to 45% have been recorded with axitinib, sunitinib, and other tyrosine kinase inhibitors. Read More ›

The results of a recent survey commissioned by AccessOne, which focused on healthcare affordability and the impact of rising costs of living, revealed that the majority (71%) of consumers feel that inflation is having a significant effect on their healthcare purchasing decisions or their ability to pay medical bills. Read More ›

During the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, a panel of experts identified some of the key challenges to achieving health equity in bladder cancer care and discussed what can be done to improve access to clinical trials, mitigate financial toxicity, and promote value-based care. Read More ›

Updated results from a large clinical trial confirm that, for some patients with bladder cancer that can be removed with surgery, receiving immunotherapy immediately afterwards is an effective treatment. Read More ›